Clinical trial
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
NCT02459301 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- Lead sponsor
- Canadian Cancer Trials Group
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 17, 2015
- Completion date
- November 12, 2019
- Enrollment
- 59 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
gynecologic cancer